

ASX Announcement

9 July 2026

ReNerve Secures up to A\$5 Million Funding Facility

Key Highlights

- Up to A\$5 million funding facility secured with RiverFort, providing ReNerve with access to staged funding over a three-year availability period.
- Initial drawdown of approximately A\$1.6 million in gross proceeds, supporting the Company's near-term commercial and operational requirements.
- Initial capital and obligations under the facility are secured by a first-ranking security interest over all present and after-acquired property of the Company, including the Company's entitlement to future R&D Tax Incentive proceeds.
- Flexible staged structure, allowing ReNerve to access capital over time as required, aligned with its commercial progress.
- The initial drawdown has a face value of A\$1.6 million and will provide approximately A\$1.361 million in net cash proceeds to the Company after the initial issue discount, drawdown fee and legal costs.
- Convertible securities issued under the facility will be limited by a maximum dilution, for the first drawdown the maximum dilution will be 16,054,394 shares, with options issued following approval at the Company's next general meeting.
- Funding to support continued commercialisation, including expansion of ReNerve's product portfolio, US sales and distribution activities, and broader market development initiatives.

ReNerve Limited (ASX, "ReNerve" or "the Company"), is pleased to announce that it has entered into a convertible note funding facility with RiverFort Global Opportunities PCC Ltd ("RiverFort") for up to A\$5 million in funding.

The facility provides ReNerve with flexible access to capital over a three-year availability period, with funds to be drawn in stages to support the Company's ongoing commercialisation strategy, working capital requirements and general corporate purposes.

ReNerve CEO Dr Julian Chick said:

"This funding facility provides ReNerve with important financial flexibility as we continue to advance our commercial and strategic objectives."



+61 (03) 9482 3940



157 Heidelberg Rd,
Northcote, VIC 3070



www.renerve.com.au

“The staged structure allows us to access capital as required, while supporting the Company’s ongoing commercialisation activities and managing dilution and cash flow.

“ReNerve has made strong progress in building its product portfolio, distribution infrastructure and market presence. This facility provides additional funding capacity as we continue to drive sales growth, support new product launches and pursue regulatory and commercial opportunities across key international markets.”

Under the terms of the facility:

- Each drawdown is issued as convertible securities with a face value of A\$1 per security, with the initial drawdown issued at a 10% discount to face value.
- The convertible securities comprising the initial drawdown will be issued using the Company’s available placement capacity under ASX Listing Rule 7.1.
- The facility provides for an initial drawdown of approximately A\$1.6 million in gross proceeds.
- The disclosed maximum dilution of 16,054,394 shares relates only to the initial drawdown. Additional shares and options may be issued in connection with future drawdowns, fee payments, option exercises and any conversions undertaken pursuant to the facility.
- Each drawdown under the facility will have a maturity date of 18 months from the date of drawdown.
- Repayment of each drawdown will occur by way of monthly cash instalments commencing six months after each relevant drawdown date.
- Outstanding balances can be converted at a fixed placing price equal to a 30% premium to the 5-day VWAP share price on the date each drawdown is advanced. For the first drawdown, the fixed placing price is 10.0849 cents.
- In the event a monthly instalment is not made in cash, the investor will be additionally granted conversion rights for the unpaid amounts at 90% of the 5-day volume weighted average price (VWAP) prior to conversion; and.
- A drawdown fee of either 4% (cash) or 5% (in shares) applies to each drawdown, at the Company’s election.
- In connection with each drawdown, the Company will issue options to RiverFort equal to 20% of the drawdown amount, exercisable at a 10% premium to the reference price and with a term of 36 months from the date of issuance.
- The Company intends to seek shareholder approval, where required, for future issuances of securities under the facility. Any further drawdowns, option issuances or conversions requiring shareholder approval will remain subject to obtaining that approval and compliance with the ASX Listing Rules.
- In the event of an uncured default, default interest may accrue at 3% per month on outstanding amounts.

The facility provides ReNerve with flexibility in relation to the settlement of repayment instalments. Instalments may be repaid in cash or, subject to the terms of the facility and compliance with the ASX Listing Rules, settled through conversion into ordinary shares in the Company.

The facility remains subject to customary conditions precedent. Further details of any securities issued or proposed to be issued under the facility will be disclosed in accordance with ReNerve’s continuous disclosure obligations.

The facility also contains customary investor protections and covenants, including restrictions on the Company incurring additional secured debt, entering into certain equity-linked financings, and granting further security interests without investor consent, as well as customary events of default and enforcement rights.

Amounts received by the Company in connection with its R&D Tax Incentive may be required to be applied toward repayment of the facility.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au


About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

On market

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.

In development

- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach \$6.2 billion by 2031.¹

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)